Filing Details
AN2 Therapeutics, Inc. (NASDAQ:ANTX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 09, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:ANTX
AN2 Therapeutics, Inc. (ANTX) Files Quarterly Report for Q0
AN2 Therapeutics, Inc. (NASDAQ:ANTX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 09, 2026.
At publication ·
What changed
AN2 Therapeutics, Inc. (NASDAQ:ANTX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- AN2 Therapeutics filed its quarterly report (Form 10-Q) with the SEC on November 09, 2026.
- The healthcare company's stock trades at $4.00 with a market capitalization of $30.1 million.
- The quarterly report includes unaudited financial statements and management commentary on business performance and conditions.
Market Context
AN2 Therapeutics, Inc.'s stock currently trades at $4.00 with a market capitalization of $30.1M.
The 10-Q provides AN2 Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for AN2 Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ANTX Stock Page
Frequently Asked Questions
Where can I read ANTX's SEC filings?
Browse all filings on our ANTX SEC filings page.
What types of SEC filings does AN2 Therapeutics, Inc. file?
Public companies like AN2 Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.